The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options ...

The FDA has approved the first generic form of liraglutide (Victoza), a once-daily injectable for improving glycemic control in patients ages 10 and older with type 2 diabetes, used as an adjunct to ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

It is expected that the FDA will soon approve this generic as an obesity treatment since the obesity drug Saxenda has the ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

Ozempic 3.0? Retatrutide — an experimental drug nicknamed “triple G” — could be your best shot at a slimmer waistline when it ...

"Saxenda has the potential to help some of these ... At the moment the only drug for obesity on the market in Europe is Roche's Xenical (orlistat), a lipase inhibitor that has been available ...

Biocon and Zentiva receive EU approval for generic versions of Victoza (diabetes) and Saxenda (weight management). This marks a significant step in providing affordable treatment options for patients.

called Saxenda. “There are many people on this drug, and they will benefit by another generic version of it,” Dr. Harlan Krumholz, a cardiologist at Yale University and Yale New Haven Hospital ...

Biocon Ltd, in collaboration with Zentiva, has obtained EU approval for the complex formulation Liraglutide, a generic version of Victoza and Saxenda, used to treat Type-2 Diabetes and weight ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...